Related Experiment Video
Updated: Jun 1, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Sorafenib-associated multivessel coronary artery vasospasm
T Naib1, R M Steingart, C L Chen
1Division of Cardiology, Memorial Sloan-Kettering Cancer Center, New York, USA.
Herz
|May 18, 2011
Summary
Vascular endothelial growth factor pathway inhibitors (VSP) can cause cardiotoxicity. This study reports the first case of sorafenib-induced multivessel coronary vasospasm, a reversible side effect.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Cancer therapies increasingly utilize VEGF signaling pathway inhibitors (VSP).
- These inhibitors target VEGFRs and other kinases crucial for vascular and myocardial homeostasis.
- Hypertension is a common side effect, but VSP-related myocardial ischemia is poorly understood.
Observation:
- A 57-year-old patient with hepatocellular carcinoma developed multivessel coronary vasospasm.
- The patient was undergoing treatment with sorafenib, a tyrosine kinase inhibitor.
- Coronary vasospasm resolved upon administration of nitroglycerin.
Findings:
- This is the first reported case of sorafenib-associated multivessel coronary vasospasm.
- Sorafenib, a VSP inhibitor, can induce coronary artery vasospasm.
- The vasospastic event was reversible with medical intervention.
Implications:
- Highlights a potential mechanism for cardiotoxicity with VSP inhibitors.
- Suggests the need for vigilance regarding coronary vasospasm in patients receiving sorafenib.
- Warrants further investigation into the mechanisms of VSP inhibitor-induced cardiovascular events.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
01:16Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...